Q & M Dental Group (QC7) Fair Value & Analysis
Healthcare · SG · Market cap 521M SGD
Fair value as of: Jul 4, 2026
From 25 valuation models · updated today
Share price −9.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.3835 SGD – 0.6350 SGD · fair‑value band 0.1600 SGD – 0.2700 SGD · the 0.5500 SGD price screens above the 0.2200 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Q & M Dental Group (QC7) currently trades at 0.5500 SGD, while our model-based Fair Value estimate is 0.2200 SGD — implying the stock looks roughly 60.0% overvalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Q & M Dental Group generated revenue of 197M SGD at a net margin of 4.7%. Revenue grew 18.5% year over year. It earns a return on equity of 8.1%. Net debt stands at 26.3M SGD. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Q & M Dental Group (Singapore) Limited, an investment holding company, provides private dental healthcare services in Singapore, Malaysia, and China. It offers various aesthetic/cosmetic, pediatric, CAD CAM digital, children, clear aligner, and implant dentistry services; consultation, gum disease and surgery, intraoral 3D scanning, oral surgery, root canal treatment, scaling and polishing, teeth grinding and whitening, tooth-coloured filling, and wisdom tooth surgery services; and crowns and bridges, dental X-rays and AI scan, dentures, extractions, mouth and night guards, orthodontics, and sensitive teeth. The company also provides general health services, including adult and children consultation, chronic disease management, men's health, and skin care services; cervical PAP smear, family planning, general and pre-marital health screening, smoking cessation, and weight loss management services; and cervical cancer, chicken pox, childhood, hepatitis profiling, tetanus, typhoid, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Q & M Dental Group reported revenue of 197M SGD in FY2025 versus 205M SGD in FY2021, a compound −1.0%/yr. Reported net income was 9.3M SGD in FY2025, compounding −25.6%/yr from FY2021.
Is QC7 fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Q & M Dental Group (QC7) undervalued?
What is the fair value of QC7?
What is the quality score of QC7?
What is the revenue of Q & M Dental Group (QC7)?
What is the net profit margin of QC7?
Does Q & M Dental Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.